text: <unk> (injection) is a methylxanthine that is FDA approved for the treatment of apnea of prematurity in infants between 28 and < 33 weeks gestational age.   Common adverse reactions include irritability, feeding problem symptom.
option_0: Caffeine citrate 
option_1: Potassium salicylate
option_2: Potassium perchlorate
option_3: Ammonium chloride
option_4: Aluminium acetotartrate
option_5: Aluminium chloride
option_6: Calcium chloride
option_7: Demecarium bromide